I now have comprehensive material from multiple authoritative textbooks. Let me compile the answer:
LV Failure in Aortic Regurgitation (AR) vs. Mitral Regurgitation (MR)
Both AR and MR impose a volume overload on the LV, but the mechanisms of LV failure differ significantly due to fundamental differences in loading conditions, compensatory geometry, and the route of regurgitation.
Shared Foundation: Volume Overload
In both lesions, the LV must pump the normal forward stroke volume plus a regurgitant volume, stretching sarcomeres toward maximum length and activating the Frank-Starling mechanism. The LV dilates (eccentric hypertrophy), increasing end-diastolic volume to maintain forward output.
How LV Failure Develops in AR
The Key Distinction: Dual Overload (Volume + Pressure)
In AR, blood leaks back through the aortic valve during diastole — directly into the LV from the high-pressure aorta. This creates a uniquely hostile hemodynamic environment not seen in MR:
1. Increased Afterload (Systolic Pressure Overload)
- The massive regurgitant stroke volume is ejected into the aorta every systole, causing a wide pulse pressure and elevated systolic aortic pressure
- This systolic hypertension creates afterload excess, which does not generally occur in MR
- The LV must therefore develop both eccentric hypertrophy (to handle volume) and concentric hypertrophy (to handle the pressure load)
- This combination results in the largest end-diastolic volumes seen in any heart disease (Guyton: stroke volumes up to 250 mL, with up to 75% regurgitating back)
2. Impaired Coronary Perfusion
- Coronary blood flow occurs predominantly in diastole
- AR causes low aortic diastolic pressure (blood runs off back into the LV) while simultaneously raising LV end-diastolic pressure
- This drastically reduces the coronary perfusion gradient (aortic diastolic pressure − LVEDP), causing subendocardial ischemia even without coronary artery disease
- Increased LV mass from combined hypertrophy further raises oxygen demand while supply is reduced → angina and ischemic myocyte loss contribute to LV dysfunction
3. The Decompensation Cascade
Progressive regurgitant load → further LV dilation → ↑ wall stress → LV hypertrophy eventually cannot keep pace → contractile dysfunction → ↓ EF, ↑ LVEDP → pulmonary congestion → CHF
From The Washington Manual:
"Steadily increasing regurgitant volume load → further ventricular dilation → ↑ wall stress → inability to continue further hypertrophy to ↓ afterload → contractile dysfunction → ↑ LVEDP → CHF symptoms (due both to congestion and ↓CO)" — The Washington Manual of Medical Therapeutics
How LV Failure Develops in MR
The Key Distinction: Low-Impedance Escape / Afterload-Sparing Mechanism
In MR, blood leaks backward through the mitral valve into the low-pressure left atrium during systole. This creates a very different hemodynamic profile:
1. Reduced Afterload (Initially)
- The regurgitant pathway allows the LV to eject into the low-impedance LA, reducing LV end-systolic wall stress
- This is why EF is typically supranormal (≥60–65%) in compensated MR — a "normal" EF actually masks underlying contractile dysfunction
- There is no systolic hypertension, no significant concentric hypertrophy — geometry is purely eccentric
2. The Three Phases of MR (Goldman-Cecil):
| Phase | Mechanism | LV Function |
|---|
| Acute | Sudden volume overload; low-impedance pathway → ↑ EF, but forward SV ↓; LA pressure spikes | EF normal or ↑, but CO ↓, pulmonary edema |
| Chronic compensated | Eccentric hypertrophy, LA dilation; forward SV normalized; patient may be asymptomatic for years | EF normal (≥60%), wall stress normalized |
| Chronic decompensated | Contractile dysfunction; ↑ ESV; but favorable loading conditions (↑ preload + low afterload) mask the true EF drop; EF may still appear "normal" despite severe contractile damage | EF may be 50–55% but contractility is severely impaired |
3. The Hidden Trap of MR
The afterload-sparing effect is the most clinically dangerous feature of MR: a patient can develop irreversible LV contractile dysfunction while the EF appears preserved or only mildly reduced. By the time EF drops below 60% or end-systolic dimension exceeds 4 cm, significant irreversible damage has already occurred. This is why MR surgery is recommended before the EF falls below 60%.
Head-to-Head Comparison
| Feature | Aortic Regurgitation | Mitral Regurgitation |
|---|
| Where blood leaks | Aorta → LV (diastole) | LV → LA (systole) |
| Type of overload | Volume + Pressure (dual) | Volume only |
| LV hypertrophy pattern | Eccentric + concentric (combined) | Purely eccentric |
| Afterload | Increased (systolic HTN) | Reduced or normal (low-impedance escape) |
| EF in decompensation | Falls clearly (EF reflects true contractility) | Remains deceptively preserved; EF of 55% = severe dysfunction |
| Coronary perfusion | Severely compromised (↓ diastolic Ao pressure, ↑ LVEDP) | Relatively preserved |
| Angina without CAD | Common — ischemia from ↓ perfusion gradient | Less common |
| LV mass | Largest of any valvular disease | Large but less than AR |
| Path to failure | Afterload excess + ischemia + contractile failure | Contractile dysfunction unmasked by loss of favorable loading |
| Acute presentation | Pulmonary edema + hypotension/shock (no time to compensate) | Pulmonary edema (LA and pulmonary pressures spike acutely) |
Key Conceptual Summary
The fundamental difference is the direction and timing of the regurgitant flow:
- In MR, blood escapes into a low-pressure chamber during systole, which reduces LV afterload and allows a long compensated phase — but masks progressive contractile failure behind a falsely preserved EF.
- In AR, blood returns from a high-pressure chamber during diastole, which adds both volume and pressure load, forces a combined hypertrophic response, and compromises coronary blood flow — ultimately causing LV failure through a combination of afterload excess, ischemia, and contractile dysfunction.
Sources: Goldman-Cecil Medicine, p. 690–694; Morgan & Mikhail's Clinical Anesthesiology, p. 772; The Washington Manual of Medical Therapeutics, p. 223–224; Guyton and Hall Textbook of Medical Physiology, p. 293